We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OGT Launches New SureSeq Myeloid Fusion Panel To Help Drive Advances in Myeloid Cancer Research

The SureSeq Myeloid Fusion Panel.
Credit: OGT.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

OGT, announces the launch of the RNA-based SureSeq™ Myeloid Fusion Panel, a new next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).


Intelligently designed in collaboration with leading myeloid cancer experts, the SureSeq Myeloid Fusion Panel ensures results meet the latest clinical research recommendations by efficiently identifying over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

This panel is fully compatible with our existing end-to-end Universal NGS Complete Workflow Solution, and complimentary data analysis software, Interpret, to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resource.


“We’re thrilled to be announcing the launch of the SureSeq Myeloid Fusion Panel, the latest addition to OGT’s growing NGS haemato-oncology portfolio” said Adrian Smith, Chief Executive Officer of OGT, “Our substantial experience with genetic technologies, combined with insights from leading myeloid cancer experts, has allowed us to develop a valuable tool for myeloid research, supported by a highly efficient workflow. This will enable users to confidently and rapidly detect the most relevant fusion genes in a single assay.”